{
  "actions": [
    {
      "acted_at": "2023-12-22",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2023-12-22",
      "action_code": "H11100",
      "committees": [
        "HSAS"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Armed Services.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr6897-118",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "Referred To"
      ],
      "committee": "House Armed Services",
      "committee_id": "HSAS"
    }
  ],
  "congress": "118",
  "cosponsors": [
    {
      "bioguide_id": "G000579",
      "district": "8",
      "name": "Gallagher, Mike",
      "original_cosponsor": true,
      "sponsored_at": "2023-12-22",
      "state": "WI",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2023-12-22",
  "number": "6897",
  "official_title": "To require the Secretary of Defense to establish a pilot program to evaluate novel pharmaceutical manufacturing technologies to reduce the reliance of the Department on foreign manufacturers for active pharmaceutical ingredients and key starting materials.",
  "popular_title": null,
  "related_bills": [],
  "short_title": "Synthetic Biology and Active Pharmaceutical Ingredients Act",
  "sponsor": {
    "bioguide_id": "S001208",
    "district": "7",
    "name": "Slotkin, Elissa",
    "state": "MI",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2023-12-22",
  "subjects": [
    "Health"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2023-12-22",
    "date": "2024-10-24T17:39:55Z",
    "text": "Synthetic Biology and Active Pharmaceutical Ingredients Act\n\nThis bill requires the Department of Defense (DOD) to establish a pilot program to support domestic manufacturing of critical pharmaceutical ingredients and their components through certain novel technology.\n\nSpecifically, DOD must establish a three-year program that uses technology involving synthetic biology to support domestic manufacturing of pharmaceutical ingredients and related incorporated materials that (1) are not available in a sufficient quantity or quality domestically, and (2) are strategically important to the United States.\n\n\u00a0"
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Synthetic Biology and Active Pharmaceutical Ingredients Act",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Synthetic Biology and Active Pharmaceutical Ingredients Act",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To require the Secretary of Defense to establish a pilot program to evaluate novel pharmaceutical manufacturing technologies to reduce the reliance of the Department on foreign manufacturers for active pharmaceutical ingredients and key starting materials.",
      "type": "official"
    }
  ],
  "updated_at": "2025-06-06T14:17:56Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/118/hr/BILLSTATUS-118hr6897.xml"
}